幽门螺杆菌粪便抗原免疫卡诊断幽门螺杆菌感染的Meta分析

目的 评价幽门螺杆菌粪便抗原免疫卡诊断幽门螺杆菌感染的精确性.方法 计算机检索Medline(1966-2007年4月)、EMbase(1985-2007年4月)和中国期刊全文数据库(1994-2007年)有关幽门螺杆菌粪便抗原免疫卡诊断幽门螺杆菌感染的临床试验,按Cochrane协作网推荐的方法进行Meta分析.结果 共11篇文献被纳入评价.合并敏感性和合并特异性分别为0.93(95%CI:0.91～0.94)、0.93(95%CI:0.90～0.95),合并阳性似然比和合并阴性似然比分别为12.01(95%CI:8.90～16.19)、0.08(95%C/:0.07～0.11).合并诊断优势比为160.14(95%CI:100.43～255.34).SROC曲线下面积为0.974±0.005.结论 幽门螺杆菌粪便抗原免疫卡是一种精确无创的诊断成年人幽门螺杆菌感染方法.

Study on the value of Helicobacter pyiori(H.pylori)stool antigen ImmunoCard STAT in the diagnosis of H.pylori infection:a Meta-analysis

OBJECTIVE: To evaluate the accuracy of the Helicobacter pylori (H. pylori) stool antigen (HpSA) test and ImmunoCard STAT HpSA in the primary diagnosis of H. pylori infection. METHODS: We searched Medline (1966-2007.4), EMbase (1985-2007.4), Chinese Journals Full-text Database (CJFD) (1994-2007) etc. to identify Clinical Trials of ImmunoCard STAT HpSA for the primary diagnosis of H. pylori infection. Meta-analysis was conducted using the method recommended by The Cochrane Collaboration Center. RESULTS: Eleven trials were included with pooled sensitivity, pooled specificity as 0.93 (95% CI: 0.91-0.94), 0.93 (95% CI: 0.90- 0.95), respectively. Pooled positive likelihood ratio and pooled negative likelihood ratio were 12.01 (95% CI: 8.90-16.19), 0.08 (95% CI: 0.07-0.11), respectively with the pooled diagnostic odds ratio as 160.14(95% CI :100.43-255.34). The area under the summary receiver operating characteristic (SROC) was 0.974 +/- 0.005. CONCLUSION: ImmunoCard STAT HpSA appeared to be an accurate non-invasive method for the initial diagnosis of H. pylori infection.